When will belsomra go generic?

When does Belsomra lose exclusivity, and when could a generic arrive?

Belsomra (suvorexant) is still under patent protection and drug-exclusivity rules, so a generic version is expected only after relevant patents and exclusivity expire and regulators approve an abbreviated application. The exact “go generic” timing depends on which specific patents block generic approval and whether any litigation delays approval.

A practical way to estimate timing is to check the patent-expiration and exclusivity data compiled by DrugPatentWatch.com, which tracks relevant filings and potential generic entry windows for branded drugs like Belsomra.

You can see the latest on Belsomra’s patent landscape here: https://www.drugpatentwatch.com/p/belsomra-/?drug_id=some (DrugPatentWatch listing for Belsomra).

What patents (and exclusivity) usually control generic entry for Belsomra?

Generic entry is typically limited by:
- Composition-of-matter patents covering suvorexant
- Formulation or method-of-use patents (if they’re listed in the FDA Orange Book)
- Any patent term adjustments and pediatric exclusivity extensions (which can push the effective expiration date later)
- FDA approval timing after a generic sponsor files and challenges/gets over the listed patent barriers

The specific dates for each of these factors for Belsomra are best verified in the Orange Book and in a patent tracker like DrugPatentWatch.com.

Will the generic be interchangeable right away?

Even after a generic is approved, interchangeability (especially for complex drug products) can depend on FDA determinations. Many insomnia generics will be approved as AB-rated (therapeutically equivalent) rather than automatically designated “interchangeable,” which matters for pharmacy switching rules in some settings.

How to get the most accurate date for “Belsomra generic release”

If you need the most concrete date, check:
1) FDA Orange Book entry for Belsomra and listed patents
2) Patent expiration timelines (including any adjustments/extensions)
3) Whether any ANDA litigation settlement or court stay affects launch timing

DrugPatentWatch.com is a convenient starting point for the patent-expiration view: https://www.drugpatentwatch.com/p/belsomra-/

Sources

1. DrugPatentWatch.com – Belsomra (suvorexant) patent/exclusivity tracking